SWM
TBPH icon

SHP Wealth Management’s Theravance Biopharma TBPH Stock Holding History

SHP Wealth Management’s Portfolio TBPH Stock Details TBPH Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-670
Closed -$12.5K – 1904
2025
Q4 		$12.5K Buy
+670
New +$11.1K ﹤0.01% 779

Other funds holding TBPH

MAP
Madison Avenue Partners New York $2.3B AUM 115.82% 1-Year Est. Return
WAM
Weiss Asset Management Boston, Massachusetts $5.91B AUM 42.42% 1-Year Est. Return
NM
Newtyn Management New York $936M AUM 27.23% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
ICM
Irenic Capital Management New York $1.54B AUM 12.79% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

SHP Wealth Management's TBPH Position: Q1 2026 in Review

SHP Wealth Management sold out of Theravance Biopharma (TBPH) in Q1 2026, closing a stake of 670 shares — an estimated $12.5K sold.

SHP Wealth Management first reported a position in TBPH in Q4 2025 and held it in 1 quarter. The position peaked at $12.5K in Q4 2025. 173 funds tracked by Wall St. Rank hold TBPH as of Q1 2026.

  • SHP Wealth Management reported no remaining Theravance Biopharma position as of Q1 2026 after selling out during the quarter.
  • SHP Wealth Management sold 670 Theravance Biopharma shares in Q1 2026, an estimated $12.5K.
  • SHP Wealth Management first reported a position in Theravance Biopharma in Q4 2025 and held it in 1 quarter.
  • SHP Wealth Management's Theravance Biopharma position peaked at $12.5K in Q4 2025.
  • 173 funds tracked by Wall St. Rank held Theravance Biopharma as of Q1 2026.

Based on SHP Wealth Management's 13F filing for Q1 2026, filed 8 May 2026.